Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2012

View Archived Issues

Safety results presented from the AMETHYST-DN study

Scientists at Myrexis synthesize new IKK-epsilon inhibitors

Gilead Sciences patents novel antiviral agents

New vaccines for tuberculosis disclosed by Alarum Development

Genmab presents novel bispecific antibodies for cancer

Allergan patents new S1P1 receptor agonists

Novel agents for HIV infection synthesized by Bristol-Myers Squibb

New antimalarial agents prepared at The Broad Institute

Brodalumab does not demonstrate meaningful clinical efficacy in patients with RA

Antitumor efficacy demonstrated for PF-05082566 in mouse model

Further data published on BAY-1000394

Phase IIb trial of AM-111 in severe hearing loss meets primary endpoint

Japanese team develops novel MAPK inhibitor for autoimmune diseases

Phase III trial of rivaroxaban for secondary prevention of cardiac events begins

PDUFA date set for Lymphoseek NDA resubmission

Interim results for CVax show encouraging immune response

Data monitoring committee recommends continuation of phase I NBTXR-3 trial

Can-Fite BioPharma to develop CF-602 for sexual dysfunction

AtheroNova partner files IND in Russia for AHRO-001

Diazyme obtains FDA clearance for use of kidney disease biomarker test

Bristol-Myers Squibb and AstraZeneca gain European approval for dapagliflozin

Committee recommends completion of PICASSO 3 trial as planned

Transgene and EORTC to collaborate on phase IIb trial of TG-4001

Pacific Therapeutics reports encouraging phase I results with combination treatment for fibrosis

Daiichi Sankyo files application in Japan for use of Inavir in prevention of influenza infection

European orphan product designation granted to algenpantucel-L

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026